Epinoma pricing

TL;DR: Epinoma does not publish a price list we can verify, which is normal for Healthcare companies at this stage. Below: what we can confirm, how to get a real quote, and 8 comparable tools to benchmark the number against.

What is verifiable about Epinoma pricing, how to get a real quote, and 8 comparable tools to price it against.

Company
Epinoma
Category
Healthcare
YC batch
Summer 2021
Status
Active
Team size
8
Public price list
Not published

Last verified:

Does Epinoma publish its pricing?

Not in any source we can verify. Epinoma is a Y Combinator-backed Healthcare company from the Summer 2021 batch, and companies at this stage usually quote per customer rather than publish rate cards. We will not guess at a number — anything quoted elsewhere without a source is guesswork too. The company profile we work from is the Y Combinator listing; the current figure has to come from Epinoma directly.

How to get an accurate Epinoma quote

  1. Ask for pricing at your actual volume, not the headline tier — per-seat and usage pricing diverge fast.
  2. Ask what happens at renewal. Uplift caps matter more than the first-year discount.
  3. Get the onboarding, migration and support costs in writing separately.
  4. Ask for a month-to-month option. If it does not exist, that tells you about the annual price.
  5. Quote a competitor from the table below. It is the fastest way to a real number.

Epinoma pricing compared to competitors

These are the closest comparable tools, matched on what Epinoma actually does. Price each one alongside it — stage and team size are a reasonable proxy for where a vendor sits on price.

Compare againstWhat it doesStageTeam
BiocognivYC Summer 20206
DocbotYC Winter 2019
Ditto BiosciencesEvolutionary intelligence for autoimmune diseaseYC Winter 20263
ExcepgenYC Winter 20193
Diffuse BioGenerative AI for protein designYC Winter 202310
SynviviaSynvivia applies chemical control over cell behaviorYC Summer 20164
Modulari-TWe teach your immune system to attack and cure cancerYC Winter 20234
TwentyTwoAI infrastructure for biosecurityYC Summer 20253

Is Epinoma worth the cost?

That depends on a number we cannot see, so judge it on what we can: Epinoma is currently Active with a team of around 8. A small team means faster support and more negotiating room, but more risk of the product changing direction. A larger or public vendor costs more and moves slower. If price is the deciding factor, the earlier-batch companies in the table are usually the ones still competing on it.

See all Epinoma alternatives compared →

Built by LemStudio

Building or buying SaaS? Try our founder tools →

Explore related

Loading interactive view…